BRPI0508078A - método para avaliar o potencial terapêutico de uma vacina para administração mucosa - Google Patents

método para avaliar o potencial terapêutico de uma vacina para administração mucosa

Info

Publication number
BRPI0508078A
BRPI0508078A BRPI0508078-9A BRPI0508078A BRPI0508078A BR PI0508078 A BRPI0508078 A BR PI0508078A BR PI0508078 A BRPI0508078 A BR PI0508078A BR PI0508078 A BRPI0508078 A BR PI0508078A
Authority
BR
Brazil
Prior art keywords
therapeutic potential
assessing
program
vaccination
vaccine
Prior art date
Application number
BRPI0508078-9A
Other languages
English (en)
Inventor
Hans Hendrik Ipsen
Lise Lund Maerkedahl
Henrik Hugo Jacobi
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of BRPI0508078A publication Critical patent/BRPI0508078A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

"MéTODO PARA AVALIAR O POTENCIAL TERAPêUTICO DE UMA VACINA PARA ADMINISTRAçãO MUCOSA". A presente invenção refere-se a um método para avaliar o potencial terapêutico de um programa de vacinação compreendendo uma vacina para administração mucosa compreendendo um ou mais antígenos e um protocolo de vacinação, o método compreendendo a) submeter no mínimo um indivíduo do teste ao programa de vacinação, b) medir o nível de um anticorpo biomarcador selecionado entre o grupo consistindo em IgA, IgG, IgE e IgX específico para o antígeno em uma amostra biológica do indivíduo do teste, e c) usar as medições obtidas para avaliar o potencial terapêutico do programa de vacinação.
BRPI0508078-9A 2004-02-26 2005-02-24 método para avaliar o potencial terapêutico de uma vacina para administração mucosa BRPI0508078A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54845404P 2004-02-26 2004-02-26
DKPA200400310 2004-02-26
US55909504P 2004-04-02 2004-04-02
PCT/DK2005/000123 WO2005083385A2 (en) 2004-02-26 2005-02-24 Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Publications (1)

Publication Number Publication Date
BRPI0508078A true BRPI0508078A (pt) 2007-07-17

Family

ID=34915878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508078-9A BRPI0508078A (pt) 2004-02-26 2005-02-24 método para avaliar o potencial terapêutico de uma vacina para administração mucosa

Country Status (8)

Country Link
EP (1) EP1718974A2 (pt)
JP (1) JP2007524096A (pt)
AU (1) AU2005217696B2 (pt)
BR (1) BRPI0508078A (pt)
CA (1) CA2556557A1 (pt)
IL (1) IL177703A0 (pt)
RU (1) RU2006134031A (pt)
WO (1) WO2005083385A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
ATE522228T1 (de) 2007-03-28 2011-09-15 Alk Abello As Verwendung einer hilfsstoffhaltigen impfstoffformulierung für subkutane verabreichung
CA2682054A1 (en) * 2007-03-28 2008-10-02 Alk-Abello A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
CN109952510A (zh) 2016-05-13 2019-06-28 应用酵素医学研究所株式会社 收集用于预测过敏发病风险的数据的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508220A (ja) * 1991-05-10 1993-11-18 ドゥ・ウエック、アラン 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用
US7888458B1 (en) * 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
HU228049B1 (en) * 1998-06-24 2012-09-28 Alk Abello As Method of detecting an antibody in a liquid sample
AU1960100A (en) * 1999-01-06 2000-07-24 Mcmaster University Method of preventing immune and hypersensitivity reactions
SE0004892D0 (sv) * 2000-12-29 2000-12-29 Pharmacia Diagnostics Ab Group 2 allergen specific IgE-Fabs and use thereof
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method
UA62780A (en) * 2003-05-22 2003-12-15 Univ Oo Bohomolets Nat Medical Method for estimating efficiency of vaccination against diphtheria in children with allergic diathesis
WO2005083385A2 (en) * 2004-02-26 2005-09-09 Alk-Abelló A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration

Also Published As

Publication number Publication date
AU2005217696A1 (en) 2005-09-09
JP2007524096A (ja) 2007-08-23
WO2005083385A3 (en) 2005-11-17
AU2005217696B2 (en) 2008-02-14
RU2006134031A (ru) 2008-04-10
EP1718974A2 (en) 2006-11-08
IL177703A0 (en) 2006-12-31
WO2005083385A2 (en) 2005-09-09
CA2556557A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
Almanzar et al. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate
Verch et al. Principles of vaccine potency assays
Tan et al. Intracellular pathogens I: chlamydiales
BRPI0508078A (pt) método para avaliar o potencial terapêutico de uma vacina para administração mucosa
Boxus et al. Antibody avidity measurements in recipients of Cervarix® vaccine following a two-dose schedule or a three-dose schedule
Samitas et al. Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes
BRPI0513596A (pt) anticorpo enriquecido para detecção de infecção micobacteriana, métodos de uso e teste diagnóstico empregando o mesmo
van Ravenhorst et al. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine
Laing et al. Respiratory disease and sero‐epidemiology of respiratory pathogens in the working horses of Ethiopia
Rendi-Wagner et al. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up
Arrazuria et al. Vaccination sequence effects on immunological response and tissue bacterial burden in paratuberculosis infection in a rabbit model
Infantino et al. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers
Cauchard et al. Assessment of the safety and immunogenicity of Rhodococcus equi-secreted proteins combined with either a liquid nanoparticle (IMS 3012) or a polymeric (PET GEL A) water-based adjuvant in adult horses and foals—identification of promising new candidate antigens
Oktay Gültekin et al. Antibody response three months after SARS‐CoV‐2 infection
Nussbaum et al. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
Tater et al. Effects of routine prophylactic vaccination or administration of aluminum adjuvant alone on allergen-specific serum IgE and IgG responses in allergic dogs
Sobrinho et al. Modified toxin-binding inhibition (ToBI) test for epsilon antitoxin determination in serum of immunized rabbits
Somogyi et al. Peptide vaccine candidate mimics the heterogeneity of natural SARS-CoV-2 immunity in convalescent humans and induces broad T cell responses in mice models
Verhagen et al. Stunting correlates with high salivary and serum antibody levels after 13-valent pneumococcal conjugate vaccination of Venezuelan Amerindian children
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
Bates et al. Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection
Moreira et al. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay
BR9509275A (pt) Processos para produzir bactéria helicobacter tendo propriedades antigênicas aumentadas testar um agente antimicrobiano potencial detectar anticorpos de um hospedeiro para bactéria helicobacter e bactéria helicobacter em um animal ou amostra biológica deste produzir anticorpos antibacterianos e estimular e estimular uma imunoresposta em um animal bactéria helicobacter vacina e estojo de teste diagnóstico para detectar um hospedeiro de anticorpos para bactéria helicobacter ou para detectar bactéria helicobacter
JP6530646B2 (ja) 頭皮の圧縮応力の評価方法
Chan et al. Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.